The blood-brain barrier and cancer:: Transporters, treatment, and Trojan horses

被引:542
作者
Deeken, John F.
Loescher, Wolfgang
机构
[1] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[2] Univ Vet Med, Dept Pharmacol Toxicol & Pharmacol, Hannover, Germany
关键词
D O I
10.1158/1078-0432.CCR-06-2854
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite scientific advances in understanding the causes and treatment of human malignancy, a persistent challenge facing basic and clinical investigators is how to adequately treat primary and metastatic brain tumors. The blood-brain barrier is a physiologic obstruction to the delivery of systemic chemotherapy to the brain parenchyma and central nervous system (CNS). A number of physiologic properties make the enclothelium in the CNS distinct from the vasculature found in the periphery. Recent evidence has shown that a critical aspect of this barrier is composed of xenobiotic transporters which extrude substrates from the brain into the cerebrospinal fluid and systemic circulation. These transporters also extrude drugs and toxins if they gain entry into the cytoplasm of brain enclothelial cells before they enter the brain. This review highlights the properties of the blood-brain barrier, including the location, function, and relative importance of the drug transporters that maintain this barrier. Primary and metastatic brain malignancy can compromise this barrier, allowing some access of chemotherapy treatment to reach the tumor. The responsiveness of brain tumors to systemic treatment found in past clinical research is discussed, as are possible explanations as to why CNS tumors are nonetheless able to evade therapy. Finally, strategies to overcome this barrier and better deliver chemotherapy into CNS tumors are presented.
引用
收藏
页码:1663 / 1674
页数:12
相关论文
共 87 条
[41]  
Kemper EM, 2003, CLIN CANCER RES, V9, P2849
[42]   Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study [J].
Korfel, A ;
Oehm, C ;
von Pawel, J ;
Keppler, U ;
Deppermann, M ;
Kaubitsch, S ;
Thiel, E .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) :1724-1729
[43]   Systemic high-dose intravenous methotrexate for central nervous system metastases [J].
Lassman, AB ;
Abrey, LE ;
Shah, GG ;
Panageas, KS ;
Begemann, M ;
Malkin, MG ;
Raizer, RJ .
JOURNAL OF NEURO-ONCOLOGY, 2006, 78 (03) :255-260
[44]  
LEE JS, 1994, MOL PHARMACOL, V46, P627
[45]   PRIMARY CHEMOTHERAPY OF BRAIN METASTASIS IN SMALL-CELL LUNG-CANCER [J].
LEE, JS ;
MURPHY, WK ;
GLISSON, BS ;
DHINGRA, HM ;
HOLOYE, PY ;
HONG, WK .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) :916-922
[46]   Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: A minor role of breast cancer resistance protein [J].
Lee, YJ ;
Kusuhara, H ;
Jonker, JW ;
Schinkel, AH ;
Sugiyama, Y .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (01) :44-52
[47]   Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme [J].
Liebner, S ;
Fischmann, A ;
Rascher, G ;
Duffner, F ;
Grote, EH ;
Kalbacher, H ;
Wolburg, H .
ACTA NEUROPATHOLOGICA, 2000, 100 (03) :323-331
[48]   Role of multidrug transporters in pharmacoresistance to antiepileptic drugs [J].
Löscher, W ;
Potschka, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :7-14
[49]   Drug resistance in brain diseases and the role of drug efflux transporters [J].
Löscher, W ;
Potschka, H .
NATURE REVIEWS NEUROSCIENCE, 2005, 6 (08) :591-602
[50]   Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases [J].
Löscher, W ;
Potschka, H .
PROGRESS IN NEUROBIOLOGY, 2005, 76 (01) :22-76